New analysis shows Inflation Reduction Act provisions will reduce Medicare Part D out-of-pocket costs for specialty drugs etanercept, ustekinumab, and ibrutinib, improving affordability for beneficiaries.

Analysis of inflation rebate implementation under the Inflation Reduction Act highlights the need to include Medicare Advantage enrollees to maximize drug cost savings and deter pharmaceutical price hikes.

Explore how the Inflation Reduction Act impacts Medicare beneficiaries' access and costs for prescription medications, including significant changes in formulary access and cost-sharing for 2025.